It achieves antibacterial effect by inhibiting the activity of bacterial DNA gyrase and hindering bacterial replication. It has broad-spectrum and strong antibacterial characteristics, and has good antibacterial effects on most Enterobacteriaceae, some Gram-positive bacteria, Legionella, Mycoplasma, Chlamydia, etc., but has poor effects on anaerobic bacteria and enterococci.

It achieves antibacterial effect by inhibiting the activity of bacterial DNA gyrase and hindering bacterial replication. It has the characteristics of broad-spectrum and strong antibacterial effect, and has good antibacterial effect on most Enterobacteriaceae, Gram-positive bacteria, Legionella, Mycoplasma, Chlamydia, etc., but has poor effect on anaerobic bacteria and enterococci.

Fluconazole is a new triazole antifungal drug with a broad-spectrum antifungal effect and can selectively inhibit fungal sterol synthesis. It is effective against Candida infections, Cryptococcus neoformans infections, Malassezia sacchari, Microsporum, Trichophyton, Epidermophyton, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, Peyer's Chromatids, and Cladosporium carinii. It has a highly selective inhibitory effect on fungal cytochrome p-450-dependent enzymes. Studies have shown that taking fluconazole has no effect on male plasma testosterone concentrations or plasma steroid concentrations in women of childbearing age, no significant effect on endogenous steroid levels or adrenocorticotropic hormone effects in healthy male volunteers, and no effect on the metabolism of antipyrine.

Fluconazole is a new triazole antifungal drug with a broad-spectrum antifungal effect. It can selectively inhibit the sterol synthesis of fungi. It is effective against Candida infection, Cryptococcus neoformans infection, Malassezia sacchariflora, Microsporum, Trichophyton, Epidermophyton, Blastomyces dermatitidis, Coccidioides immitis, Histoplasma capsulatum, Peyer's Chromatid, and Cladosporium carinii. It has a highly selective inhibitory effect on fungal cytochrome p-450-dependent enzymes.

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the transfer of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.